-
Innovation Ranking
NewInnovation Ranking – Kala Pharmaceuticals Inc
Kala Pharmaceuticals Inc (Kala Pharmaceuticals) is a clinical stage pharmaceutical company. It offers nanoparticle-based treatments for ocular diseases affecting both front and back of the eye. The company’s AMPPLIFY technology, treats the medical needs for the front of the eye, and NCEs, targeted to address front and back of the eye diseases. Its pipeline products includes EYSUVIS (loteprednol etabonate ophthalmic suspension), is used for the treatment of short-term (up to two weeks) treatment of the signs and symptoms of dry...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – LXE-408 in Leishmaniasis (Kala-Azar)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LXE-408 in Leishmaniasis (Kala-Azar) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LXE-408 in Leishmaniasis (Kala-Azar) Drug Details: LXE-408 is under development for the...
-
Product Insights
Leishmaniasis (Kala-Azar) – Drugs In Development, 2023
Global Markets Direct’s, ‘Leishmaniasis (Kala-Azar) - Drugs In Development, 2023’, provides an overview of the Leishmaniasis (Kala-Azar) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Leishmaniasis (Kala-Azar), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewNet Present Value Model: KALA BIO Inc’s KPI-012
Empower your strategies with our Net Present Value Model: KALA BIO Inc's KPI-012 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Kala Pharmaceuticals Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Kala Pharmaceuticals Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Paromomycin in Leishmaniasis (Kala-Azar)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Paromomycin in Leishmaniasis (Kala-Azar) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Paromomycin in Leishmaniasis (Kala-Azar) Drug Details: Paromomycin is under development for...
-
Analyst Opinions
NewMobile World Congress (MWC) 2024 – Startups Race for Digital Change
GlobalData's latest report, "MWC 2024: Startups Race for Digital Change," dives into the innovation trends showcased by startup exhibitors at MWC 2024. With a focus on AI's pivotal role, it highlights how AI startups are shaping industry innovation and attracting investor interest. Additionally, it explores fintech, digitalization, IoT, and healthtech startups' contributions. By delving into the latest advancements, unique offerings, and venture capital activities of over 40 startups, this report serves as a valuable resource for stakeholders seeking to navigate...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GSK-3494245 in Leishmaniasis (Kala-Azar)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GSK-3494245 in Leishmaniasis (Kala-Azar) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GSK-3494245 in Leishmaniasis (Kala-Azar) Drug Details: GSK-3494245 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KPI-012 in Persistent Corneal Epithelial Defects
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KPI-012 in Persistent Corneal Epithelial Defects report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KPI-012 in Persistent Corneal Epithelial Defects Drug Details: KPI-012...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DB-1303 in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DB-1303 in Endometrial Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DB-1303 in Endometrial Cancer Drug Details: DB-1303 is under development for...